Patents by Inventor Brian Blagg

Brian Blagg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HSP90 activator AHA1 drives production of pathological tau aggregates
    Patent number: 11931373
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 19, 2024
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES
    Publication number: 20220241309
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 4, 2022
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • Hsp90 activator Aha1 drives production of pathological tau aggregates
    Patent number: 11318155
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 3, 2022
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Blair
  • HSP90 BETA SELECTIVE INHIBITORS
    Publication number: 20210269418
    Abstract: Described are compounds of formula (I), based on an isoquinolin-1(2H)-one backbone, that function as Hsp90? selective inhibitors. Also described are pharmaceutical compositions thereof and methods of treating cancer by administering compounds of formula (I).
    Type: Application
    Filed: May 30, 2019
    Publication date: September 2, 2021
    Inventors: Brian Blagg, Sanket Mishra
  • THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES
    Publication number: 20210128597
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: February 23, 2018
    Publication date: May 6, 2021
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Blair
  • Novobiocin analogues
    Patent number: 8212011
    Abstract: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders, as well as cancer.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: July 3, 2012
    Assignee: University of Kansas
    Inventor: Brian Blagg
  • Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
    Patent number: 7622451
    Abstract: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: November 24, 2009
    Assignee: University of Kansas
    Inventors: Brian Blagg, Mary Lou Michaelis, Michelle McIntosh
  • Heat shock protein 90 inhibitors
    Patent number: 7605288
    Abstract: Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: October 20, 2009
    Assignee: University of Kansas
    Inventors: Brian Blagg, Gang Shen, Randell C. Clevenger
  • Novobiocin Analogues
    Publication number: 20090187014
    Abstract: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders, as well as cancer.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 23, 2009
    Inventor: Brian Blagg
  • Novobiocin Analogues Having Modified Sugar Moieties
    Publication number: 20090163709
    Abstract: Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.
    Type: Application
    Filed: February 20, 2009
    Publication date: June 25, 2009
    Inventor: Brian Blagg
  • Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
    Publication number: 20070270452
    Abstract: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.
    Type: Application
    Filed: May 10, 2007
    Publication date: November 22, 2007
    Inventors: Brian Blagg, Mary Michaelis, Michelle McIntosh
  • Heat shock protein 90 inhibitors
    Publication number: 20070197787
    Abstract: Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.
    Type: Application
    Filed: March 26, 2007
    Publication date: August 23, 2007
    Inventors: Brian Blagg, Gang Shen, Randell Clevenger
  • Heat shock protein 90 inhibitors
    Patent number: 7208630
    Abstract: Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: April 24, 2007
    Assignee: University of Kansas
    Inventors: Brian Blagg, Gang Shen, Randell C. Clevenger
  • Novobiocin analogues as anticancer agents
    Publication number: 20060199776
    Abstract: Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.
    Type: Application
    Filed: November 3, 2005
    Publication date: September 7, 2006
    Inventors: Brian Blagg, Len Neckers, Xiao Yu
  • Heat shock protein 90 inhibitors
    Publication number: 20060089495
    Abstract: Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.
    Type: Application
    Filed: October 27, 2004
    Publication date: April 27, 2006
    Inventors: Brian Blagg, Gang Shen, Randell Clevenger